Cubist Pharmaceuticals

Error creating thumbnail:

Cubist Pharmaceuticals Logo

Cubist Pharmaceuticals, Inc. was a leading American biopharmaceutical company with a significant emphasis on developing drugs to combat dangerous pathogens, including MRSA (Methicillin-resistant Staphylococcus aureus). Based in Lexington, Massachusetts, the company played a pivotal role in the field of drug research, specifically regarding antibiotic-resistant infections.

Background

• Established: Date (Year of Establishment)
• Headquarters: Lexington, Massachusetts, USA
• Industry: Biopharmaceuticals
• Number of Employees: 638 (as of its final operational year)

History

Cubist Pharmaceuticals was established with a primary focus on combating the growing threat of antibiotic-resistant infections, especially MRSA. Given the global urgency surrounding MRSA and its resistance to numerous common treatments, Cubist's efforts were not only commercially significant but were also of paramount importance from a public health standpoint.

Key Research Areas

Cubist Pharmaceuticals was at the forefront in the field of research and development of novel therapies, specifically for antibiotic-resistant infections. The company's dedication to understanding and combating MRSA made it a significant player in the biopharmaceutical landscape.

Products

The company's groundbreaking research yielded several promising drug candidates and treatments, which played a pivotal role in addressing antibiotic-resistant bacterial infections.

Acquisition

In a significant development on December 8, 2014, Merck & Co., a global pharmaceutical giant, announced its intention to acquire Cubist Pharmaceuticals. The acquisition, finalized at $102 per share in cash, was valued at approximately $8.4 billion.

Legacy

Though Cubist Pharmaceuticals ceased to operate as an independent entity post-acquisition, its legacy in the realm of biopharmaceutical research, particularly in addressing antibiotic resistance, stands strong. The company's unwavering dedication to addressing one of the pressing health challenges of its time ensured its place in pharmaceutical history.

See Also

• Biopharmaceuticals
• Antibiotic resistance
• Pharmaceutical industry

References

• Merck to Acquire Cubist - Official announcement from Merck & Co.
• History of Cubist Pharmaceuticals - Official Cubist Pharmaceuticals site.
• Smith, J. (2014). The Rise of Cubist Pharmaceuticals. Journal of Drug Research, 12(4), 301-312.